Florentine Moazedi‐Fuerst

Results from a Novel Ongoing Prospective Screening Algorithm for Patients at risk for Interstitial Lung Disease

Katarina Zeder, Florentine Moazedi‐Fuerst, Bernd Bohr, Philipp Douschan et autres

Rationale: To date there is no validated screening algorithm that informs on chest CT timing in patients at risk for interstitial lung disease (ILD). Method: We initiated a novel prospective ILD screening algorithm. At inclusion all patients received a non-contrast prone HR-chest …

at (code pays fourni par la source)

Endothelial function and vascular events in patients with limited cutaneous systemic sclerosis (EFVELSS): a prospective observational study

Philipp Jud, Philipp Douschan, Teresa Sassmann, Günther Silbernagel et autres

Evaluating the predictive role of endothelial dysfunction in the development of vasculopathy-mediated complications in patients with limited cutaneous systemic sclerosis (lcSSc). 38 patients with lcSSc who were naïve for vasculopathy-mediated complications, defined as absent pre-existing digital ulcers (DU), pulmonary hypertension (PH) and …

at, us (code pays fourni par la source)

POS1109 USE OF LUNG ULTRASOUND FOR SCREENING FOR SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASES IN CENTRAL AND EASTERN EUROPE

Maria Sanzharovskaya, Yochai Adir, Alan Altraja, R. Bekenova et autres

Background: Lung ultrasound (LUS) is a promising tool for screening for interstitial lung disease (ILD) in patients with systemic autoimmune rheumatic diseases (SARDs). However, data on the frequency of its use as a screening tool in clinical practice are limited. Objectives: To …

at, il, ee, kz, lv, ua, rs, sk, hr, bg, cz, pl, hu, ro (code pays fourni par la source)

AB1202 SUCCESSFUL LONG-TERM TREATMENT OF SYSTEMIC SCLEROSIS BY HIGH-FREQUENT, LOW-DOSE B CELL DEPLETING THERAPY

Florentine Moazedi‐Fuerst, A. Lackner, Sebastian Kreuzer, Kathrin Eller et autres

at, de (code pays fourni par la source)

Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy

Florentine Moazedi‐Fuerst, A. Lackner, Sonja Kreuzer, Kathrin Eller et autres

OBJECTIVES: Systemic sclerosis (SSc) is a multiorgan disease with a 10-year mortality rate of up to 50 %. B cell-depleting therapy with rituximab (RTX) appears effective in SSc treatment, but data from randomized controlled trials (RCTs) are lacking, and the frequency and …

at, de (code pays fourni par la source)

Wertigkeit der CT und des transthorakalen Lungenultraschalls bei PatientInnen mit systemischer Sklerose

Michael Grohs, Florentine Moazedi‐Fuerst, Holger Flick, Klaus Hackner et autres

Lung involvement is the most frequent cause of death in patients with systemic sclerosis (SSc). As lung involvement is frequently asymptomatic, the current recommendation is to carry out thoracic computed tomography (CT) in all patients newly diagnosed with SSc. There is currently …

at, de (code pays fourni par la source)

Effect of short‐interval rituximab and high‐dose corticosteroids on kidney function in systemic sclerosis: Long‐term experience of a single centre

Balazs Odler, Carina Hebesberger, Lukas Hoeflechner, Gudrun Pregartner et autres

Abstract Introduction Scleroderma renal crisis (SRC) is a rare but one of the most recognised complications of systemic sclerosis (SSc). Corticosteroid (CS) use has been considered as a major risk factor for SRC. Several studies reported the efficacy of rituximab (RTX) with …

at (code pays fourni par la source)

SARS-CoV-2 positive virus culture 7 weeks after onset of COVID-19 in an immunocompromised patient suffering from X chromosome-linked agammaglobulinemia

Katharina Guetl, Florentine Moazedi‐Fuerst, Konrad Rosskopf, Marianne Brodmann et autres

at (code pays fourni par la source)

Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis

Katarina Zeder, Alexander Avian, Gerhard Bachmaier, Philipp Douschan et autres

at (code pays fourni par la source)

The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements

Anna‐Maria Hoffmann‐Vold, Toby M. Maher, E. Philpot, Ali Ashrafzadeh et autres

no, gb, us, it, es, de, fr, cz, at, ch, pl (code pays fourni par la source)

A patient with predominant interstitial nephritis as a renal manifestation of systemic lupus erythematosus

Balazs Odler, Marion J. Pollheimer, Alexander H. Kirsch, Florentine Moazedi‐Fuerst et autres

Sir, Kidney involvement is one of the leading causes of overall morbidity and mortality in patients with SLE [1]. The manifestations, progression and outcomes of LN are heterogeneous, however, 10–20% of patients will progress to end-stage renal disease within 5 years of …

at (code pays fourni par la source)

Helpful, albeit hazardous! Esophageal stem-cell injection in systemic sclerosis

Franziska Durchschein, Florentine Moazedi‐Fuerst, Sonja Kielhauser, Angelika Lackner et autres

BACKGROUND: Over 90% of patients with systemic sclerosis suffer from gastroesophageal reflux. Esophageal motility disturbances are associated with a reduced life quality and may force interstitial lung disease progression. We wanted to determine whether we can improve gastroesophageal reflux in these patients …

at (code pays fourni par la source)